ArticleJournal of clinical medicine2020
Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Relationship between morphine rescue dose and respiratory safety during breakthrough cancer pain in lung cancer patients treated with high-dose opioids.American journal of cancer research · 2026Article
- Patterns and Associated Factors of Breakthrough Pain in Lung Cancer: Insights From a Cross-Sectional Study With Prospective Enrollment.Pain research & management · 2026Article
- A scoping review of breakthrough cancer pain: Multidimensional patient needs and influencing factors.Asia-Pacific journal of oncology nursing · 2025Review
- Scheduled and Breakthrough Opioid Use for Cancer Pain in an Inpatient Setting at a Tertiary Cancer Hospital.Current oncology (Toronto, Ont.) · 2024Article
- High-rate breakthrough cancer pain and tumour characteristics - literature review and case series.Drugs in context · 2023Review
- Relationship between breakthrough cancer pain, background cancer pain and analgesic treatment - case series and review of the literature.Drugs in context · 2022Review
- Efficacy of adenosylmethionine combined with Si Mo Tang in treatment of neonatal jaundice.American journal of translational research · 2022Article
- Retrospective Observational Study on the Characteristics of Pain and Associated Factors of Breakthrough Pain in AdvancedPain research & management · 2022Observational
- Application effects of evidence-based nursing in pain nursing of advanced lung cancer.American journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo characterize breakthrough cancer pain (BTcP) in patients with lung cancer.
methodsThis was a secondary analysis of multicenter study of patients with BTcP. Background pain intensity and opioid dose were recorded. The number of BTcP episodes, their intensity, predictability, onset, duration and interference with daily activities were collected. Opioids used for BTcP, the mean time to meaningful pain relief after taking medication, satisfaction and adverse effects were assessed.
results1087 patients with lung cancer were examined. In comparison with other tumors, patients with lung cancer showed: higher background pain intensity (
conclusionPatients with lung cancer have their own peculiarities, including higher basal and BTcP pain intensity and the use of more adjuvant drugs for background pain. The most frequent triggers for predictable BTcP are movement and cough. Future studies should be performed to analyze the prevalence of BTcP in patients with different lung cancers as well as the optimal management strategy for background pain and BTcP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.